OncoMatch/Clinical Trials/NCT06682728
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence
Is NCT06682728 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Sacituzumab Govitecan (SG) and Nivolumab for urothelial carcinoma.
Treatment: Sacituzumab Govitecan (SG) · Nivolumab — This is a phase 2 study, single-arm study of adjuvant combination therapy with Sacituzumab Govitecan and Nivolumab in patients with muscle-invasive urothelial carcinoma of the bladder, ureter, or upper tract, who are high risk for cancer recurrence post curative-intent surgery based on surgical pathology.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: surgery — curative-intent
Underwent curative-intent surgery (i.e. RC or nephroureterectomy), performed within 180 days prior to study treatment initiation.
Cannot have received: adjuvant platinum-based chemotherapy
History of adjuvant platinum-based chemotherapy or any other type of adjuvant therapy, including investigational agents, following surgical removal of UC.
Cannot have received: adjuvant therapy
History of adjuvant platinum-based chemotherapy or any other type of adjuvant therapy, including investigational agents, following surgical removal of UC.
Cannot have received: PD-1 inhibitor
History of treatment with PD-1/PD-L1 inhibitors or sacituzumab govitecan prior to study treatment initiation.
Cannot have received: PD-L1 inhibitor
History of treatment with PD-1/PD-L1 inhibitors or sacituzumab govitecan prior to study treatment initiation.
Cannot have received: antibody-drug conjugate (sacituzumab govitecan)
History of treatment with PD-1/PD-L1 inhibitors or sacituzumab govitecan prior to study treatment initiation.
Cannot have received: radiation therapy
History of previous radiation therapy for treatment of UC.
Lab requirements
Blood counts
anc ≥ 1000/mcl; platelets ≥ 100,000/mcl; hemoglobin ≥ 9.0 g/dl; aptt ≤ 1.5 × institutional uln
Kidney function
creatinine clearance of ≥30 ml/min (calculated with cockroft-gault formula)
Liver function
total bilirubin ≤ 1.5 × institutional uln (or ≤ 3.0 × uln for subjects with gilbert's disease); ast/alt ≤ 3 × institutional uln; alkaline phosphatase ≤ 3 × institutional uln; serum albumin ≥ 2.8 g/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Chao Family Comprehensive Cancer Center, University of California, Irvine · Orange, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify